These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11548841)

  • 1. The CD3- 16+ 56+ NK cell count independently predicts autologous blood stem cell mobilization.
    Stewart DA; Guo D; Luider J; Auer I; Klassen J; Morris D; Brown CB; Chaudhry A; Glück S; Russell JA
    Bone Marrow Transplant; 2001 Jun; 27(12):1237-43. PubMed ID: 11548841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
    Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
    Liu JH; Chen CC; Bai LY; Chao SC; Chang MS; Lin JS
    J Chin Med Assoc; 2008 Jun; 71(6):279-85. PubMed ID: 18567557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield.
    Marques JF; Vigorito AC; Aranha FJ; Lorand-Metze I; Miranda EC; Lima Filho EC; Valbonesi M; Santini G; De Souza CA
    Transfus Sci; 2000 Oct; 23(2):91-100. PubMed ID: 11035269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.
    Akard LP; Thompson JM; Dugan MJ; Wiemann M; Greenspan A; Hanks S; Swinney M; Nyhuis A; Jansen J
    Biol Blood Marrow Transplant; 1999; 5(6):379-85. PubMed ID: 10595815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
    Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R
    J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
    Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R
    Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.